Literature DB >> 21535316

MRG-binding protein contributes to colorectal cancer development.

Kiyoshi Yamaguchi1, Michihiro Sakai, JooHun Kim, Shin-ichiro Tsunesumi, Tomoaki Fujii, Tsuneo Ikenoue, Yoshinao Yamada, Yoshiyuki Akiyama, Yasuhiko Muto, Rui Yamaguchi, Satoru Miyano, Yusuke Nakamura, Yoichi Furukawa.   

Abstract

MRGBP (MORF4-related gene-binding protein; also known as chromosome 20 open reading frame 20) encodes a subunit of the transformation/transcription domain-associated protein (TRRAP)/tat-interacting protein 60 (TIP60)-containing histone acetyltransferase complex. We previously showed that MRGBP was upregulated in the majority of colorectal tumors, and the enhanced expression was associated with cell proliferation. In this study, we investigated its role in colorectal carcinogenesis and searched for genes regulated by MRGBP. Immunohistochemical staining of 22 adenomas and 47 carcinomas in the colon and rectum showed that high levels of MRGBP expression were observed more frequently in carcinomas (45%) than adenomas (5%), linking its role to malignant properties of colorectal tumors. No clinicopathological factors were associated with the levels MRGBP expression in colorectal cancer. Copy number analysis revealed that gene amplification is involved in the elevated expression. A genome-wide expression analysis identified a total of 41 genes upregulated by MRGBP. These genes were implicated in biological processes, including DNA replication, minichromosome maintenance, and cell division. Theses results suggest that MRGBP contributes to colorectal carcinogenesis through rendering advantages in cell proliferation and/or division of cancer cells. Our findings might be helpful for the identification of a specific biomarker for colorectal cancer and the development of diagnostic and/or therapeutic approaches.
© 2011 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21535316     DOI: 10.1111/j.1349-7006.2011.01971.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  5 in total

1.  MRGBP is a potential novel prognostic biomarker and is correlated with immune infiltrates in hepatocellular carcinoma.

Authors:  Juanjun Huang; Xiaoli Chen; Wei Zhu
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

2.  The aspirin metabolite salicylate inhibits lysine acetyltransferases and MUC1 induced epithelial to mesenchymal transition.

Authors:  Harvey R Fernandez; Sara K Lindén
Journal:  Sci Rep       Date:  2017-07-17       Impact factor: 4.379

3.  High-throughput screening and genome-wide analyses of 44 anticancer drugs in the 1000 Genomes cell lines reveals an association of the NQO1 gene with the response of multiple anticancer drugs.

Authors:  Farida S Akhtari; Adrian J Green; George W Small; Tammy M Havener; John S House; Kyle R Roell; David M Reif; Howard L McLeod; Timothy Wiltshire; Alison A Motsinger-Reif
Journal:  PLoS Genet       Date:  2021-08-26       Impact factor: 5.917

4.  MRGBP: A New Factor for Diagnosis and Prediction of Head and Neck Squamous Cell Carcinoma.

Authors:  Cheng Zhao; Chuang Wei; Xiatian Chen; Peifeng Li
Journal:  Biomed Res Int       Date:  2022-07-25       Impact factor: 3.246

5.  MRGBP as a potential biomarker for the malignancy of pancreatic ductal adenocarcinoma.

Authors:  Feng Ding; Shuang Zhang; Shaoyang Gao; Jian Shang; Yanxia Li; Ning Cui; Qiu Zhao
Journal:  Oncotarget       Date:  2017-07-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.